We would love to hear your thoughts about our site and services, please take our survey here.
https://www.google.com/amp/s/www.bbc.com/sport/formula1/61786715.amp
hopefully it geos ahead... and in turn bring more interest formula e
Private Power and Infrastructure Board Meeting with Consortium Scheduled
Oracle Power PLC (AIM:ORCP) is pleased to advise that, further to the announcement of 28 August 2020, the Company, along with its Consortium partners, China National Coal Development Company Ltd. and the private office of His Highness Sheikh Ahmed Bin Dalmook Juma Al Maktoum (together, the'Consortium'), has been invited to meet with the Private Power and Infrastructure Board ('PPIB') on Friday, 11 September 2020. The purpose of the meeting is for the Consortium to formally present the Thar Block VI project implementation plan, with a view to finalising the award of a Letter of Intent ('LOI').
The meeting will be chaired by the Special Assistant to the Prime Minister on Power in Islamabad, Pakistan, along with representatives of the Ministry of Energy (Power Division), CPEC Authority and the Planning Commission (Islamabad). The Consortium will present plans to the government for the development of Thar Block VI for power, gas for urea and other uses.
The Consortium's presentation to the PPIB forms part of its LOI application and is considered by the Board of Oracle as one of the final steps in the award of the LOI. Further updates in respect of the timing, and next steps required, with regard to the issuance of the LOI will be made in due course as and when appropriate.
Its... all pending on the arms the 4 arms i know of in the solidarity trail are
1.Remdisiver
2.Hydroxy(stopped)
3.Lopinavir/ritonavir(stopped)
4 Lopinavir/ritonavir with interferon(stopped)
The current news going around(solidarity trail)is they have stopped 2- 3-4 ...
"After the inclusions in the hydroxychloroquine arm stopped, both arms testing the lopinavir/ritonavir combination with or without interferon beta were stopped in the Solidarity and Discovery clinical trials. Given the adaptive nature of the Solidarity trial and its European Discovery “daughter” trial, a reflection is underway on the evolution of the protocol. Publications in international peer-reviewed journals are in preparation concerning both the evaluation of hydroxychloroquine and lopinavir/ritonavir."
But this looks promising for remdesiver and interferon cant quite decipher the last sentence either it means
"A communication in the form of publications in international peer-reviewed journals will detail the results. In addition, given the adaptive nature of the Solidarity trial and its European “daughter” trial Discovery, a reflection is underway on the evolution of the protocol. In addition to the ongoing evaluation of Remdesivir and interferon, this includes the possibility of testing new treatments"
Cant decipher the last sentence either it means new testing for remsdiver and interferon or some sort new drug .
Let see whay monday brings, looks like it will be massive carnage 1st thing... hopefully Faron release a RNS to steady the ship and its position in the trails
Gla
https://presse.inserm.fr/en/discovery-stopping-inclusions-in-two-treatment-groups/40087/
Did traukimine/ interfreon have its own arm?... if they did then Breaking the sentence down looks like its still gota chance
"both arms testing the lopinavir/ritonavir combination with or without interferon beta were"
looks like testing lopiavir/ritonavir had two arms one with interferon and with out, and both failed... so it looks like they are pulling out lopinavir/ritonavir
Just hoping that interferon had its on arm
Company announcement, 28 May 2020 at 9.00 AM (EET)
TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT.
The event will provide an opportunity for the Company's management team to present its R&D strategy and provide insight into Faron's two clinical stage programmes. Management will discuss the Company's wholly-owned novel precision cancer immunotherapy, Clevegen, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. Management will also discuss Traumakine, for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), which is currently being investigated in COVID-19 patients in the ongoing REMAP-CAP trial and the WHO's Solidarity trial. There will be an opportunity to ask questions during the webcast.
For further information on the R&D Day, or to register for the event, please contact Consilium Strategic Communications at faron@consilium-comms.com or telephone +44 (0)20 3709 5700.
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 3,500 ordinary shares in Faron at a price of €4.3255 per share on 12 May 2020. Following these purchases, Mr Hänninen holds 50,297 ordinary shares in the Company.